GlassScriptPhysician profile
Barbara A Bentz
NPI 1538117262
$2,630.37
in general payments reported to CMS, 2019-2025
15 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $434 · 2023: $274 · 2024: $688 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $665.48 | 2021-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $475.52 | 2021-2024 | Xarelto |
| Abbott Laboratories | $321.74 | 2023-2024 | Cardiomems |
| Boston Scientific Corporation | $245.20 | 2022 | |
| Amgen INC. | $233.10 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $143.08 | 2024-2025 | Farxiga |
| Axsome Therapeutics, INC. | $124.00 | 2025 | |
| Daiichi Sankyo INC. | $118.26 | 2023-2024 | Injectafer |
| Novo Nordisk INC | $109.62 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.23 | 2024 | Lifevest |
| Atricure, INC. | $44.80 | 2025 | Atriclip Laa Exclusion System |
| Actelion Pharmaceuticals US, INC. | $27.91 | 2025 | Uptravi |
| Merck Sharp & Dohme LLC | $14.93 | 2024 | Verquvo |
| Akcea Therapeutics, INC. | $11.16 | 2021 | |
| Cvrx, INC. | $10.34 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Bentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.